MMSIHealthcare · Medical Instruments & SuppliesThe 11 Wall Street analysts covering Merit Medical Systems, Inc. hold a median 12-month price target of $100 — +6.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 26 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Merit Medical Systems, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (95): Analysts have, on balance, been raising their forecasts.
Accruals (54): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (21): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on MMSI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +6.9% from it.
Of the 20 most recent actions, 7 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Sept 2026 | Needham | Reiterates | Buy | $101 |
| 13 Aug 2026 | B of A Securities | Maintains | Neutral | — |
| 13 Aug 2026 | B of A Securities | Maintains | Neutral | $92 → $97 |
| 11 Aug 2026 | BTIG | Reiterates | Buy | $105 |
| 11 Aug 2026 | BTIG | Reiterates | Buy | — |
| 3 Aug 2026 | Canaccord Genuity | Maintains | Buy | — |
| 3 Aug 2026 | Canaccord Genuity | Maintains | Buy | $85 → $94 |
| 31 July 2026 | BTIG | Maintains | Buy | — |
| 31 July 2026 | BTIG | Maintains | Buy | $100 → $105 |
| 31 July 2026 | JP Morgan | Maintains | Overweight | $77 → $95 |
| 31 July 2026 | JP Morgan | Maintains | Overweight | — |
| 31 July 2026 | Needham | Maintains | Buy | — |
| 31 July 2026 | Needham | Maintains | Buy | $90 → $101 |
| 31 July 2026 | Piper Sandler | Maintains | Overweight | $96 → $106 |
| 31 July 2026 | Piper Sandler | Maintains | Overweight | — |
| 31 July 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 31 July 2026 | Wells Fargo | Maintains | Equal-Weight | $74 → $83 |
| 1 May 2026 | Canaccord Genuity | Maintains | Buy | $90 → $85 |
| 1 May 2026 | Canaccord Genuity | Maintains | Buy | — |
| 1 May 2026 | JP Morgan | Maintains | Overweight | $95 → $77 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
MMSI appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 27 Oct 2026, Merit Medical Systems, Inc. returned +13.0% against +13.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 19% of US stocks
Cheaper than 33% of US stocks
Cheaper than 28% of US stocks
Cheaper than 18% of US stocks
Higher than 52% of US stocks
Higher than 58% of US stocks
Higher than 64% of US stocks
Higher than 72% of US stocks
Higher than 68% of US stocks
Higher than 61% of US stocks
Higher than 76% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Merit Medical Systems, Inc. has a market value of $5.6B and an enterprise value of $5.9B.
Revenue in the twelve months to 30 June 2026: $1.6B. The latest quarter grew 9.5% year on year.
Net income over the same four quarters: $145.6M, a 9.2% net margin.
Diluted earnings per share, trailing twelve months: $2.42.
Free cash flow in the twelve months to 30 June 2026: $199.8M, after $83.7M of capital spending.
Trailing P/E: 38.8×; forward P/E: 20.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Merit Medical Systems, Inc. employs 7,500 people — $211K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Merit Medical Systems, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
The Conestoga Small Cap Composite returned -11.22% net of fees in 3Q26, versus -9.39% for the Russell 2000 Growth Index. Merit Medical was listed among the composite’s top five leaders.
Why it matters — MMSI watchers may note Merit Medical’s inclusion among the portfolio’s leading stocks during the quarter.
Zacks Investment Research notes that oncology stocks are gaining relevance as cancer care evolves, highlighting Pfizer, Merit Medical Systems and Abbott for advancing treatments, diagnostics and screening technologies.
Why it matters — The item includes Merit Medical Systems among companies advancing technologies related to cancer care.
Merit Medical Systems said it will report results for the quarter ended September 30, 2026, after market close on October 29, 2026. The company will hold an investor conference call that day at 4:30 p.m. Eastern.
Why it matters — MMSI watchers can note the scheduled date and time for the quarterly results and investor call.
A Zacks Investment Research item compares Henry Schein (HSIC) and Merit Medical (MMSI) as potential value stocks in the Medical - Dental Supplies sector, asking which offers the better value opportunity.
Why it matters — MMSI watchers may be interested in the comparison of the company with HSIC on value.
Zacks Investment Research highlights Merit Medical’s broad product portfolio, global expansion and strategic M&A as growth supports, while noting tariffs and pressures in China as key risks.
Why it matters — MMSI watchers may weigh these growth drivers against trade and China-related risks.
The 11 Wall Street analysts covering Merit Medical Systems, Inc. have a median 12-month price target of $100, with estimates ranging from $83 to $123. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering Merit Medical Systems, Inc., 9 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Merit Medical Systems, Inc. 93 out of 100 across roughly 4,600 US stocks as at 26 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 26 Oct 2026, Merit Medical Systems, Inc. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (95 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies +6.9% from the last close, and Ticker Nerd's factor model ranks Merit Medical Systems, Inc. 93 out of 100 as at 26 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Merit Medical Systems, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MMSI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $83 to $123 over the next 12 months.
Merit Medical Systems, Inc. returned +13.0% over the 12 months to 27 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Merit Medical Systems, Inc. is a medical device company that develops, manufactures, and markets disposable products used in interventional, diagnostic, and therapeutic procedures.
The most recent item we track (Seeking Alpha, 27 Oct 2026): "Conestoga Small Cap Composite Q3 2026 Portfolio Activity". The Conestoga Small Cap Composite returned -11.22% net of fees in 3Q26, versus -9.39% for the Russell 2000 Growth Index. Merit Medical was listed among the composite’s top five leaders.
Merit Medical Systems, Inc. is a medical device company that develops, manufactures, and markets disposable products used in interventional, diagnostic, and therapeutic procedures. Merit Medical Systems, Inc. serves a wide range of clinical specialties through its Cardiovascular and Endoscopy segments, with offerings that support cardiology, radiology, oncology, critical care, gastroenterology, pulmonology, and thoracic surgery. Its product portfolio includes access devices, drainage and embolotherapy tools, guide wires, balloon dilators, inflation devices, procedure kits, hemostasis solutions, and other single-use technologies designed for minimally invasive care. The company also provides products used in interventional oncology, spine procedures, cardiac rhythm management, electrophysiology, and cardiovascular critical care. Headquartered in South Jordan, Utah, Merit Medical Systems, Inc. plays a role in supplying hospitals, clinicians, and procedure centers with specialized tools for modern medical interventions.
CEO Ms. Martha Goldberg Aronson · 7,500 employees · United States · https://www.merit.com
